The Scientific Review Committee of the American Association for Cancer Research (AACR) foundation approved funding for the project, entitled “Cancer-specific Metabolic Complex for Small Molecule Drug Discovery.” Dr. An formally accepted the grant at the 2016 AACR Annual Meeting in New Orleans, and he posed with Dr. Jose Baselga, Immediate Past President of the AACR (right), and Dr. Karl Ziegelbauer, Senior Vice President and Head, Therapeutic Research Groups of Bayer (left). Dr. An and his team anticipate to generate a novel class of drugs that influence the metabolic flux of glucose metabolism through its spatial assembly, without inhibiting the canonical activities of individual enzymes, for therapeutic intervention.